How this turnaround specialist aims to scale a high-tech Aussie remote-comms firm to profitability and beyond
Harvest Technology’s remote-communications solution is an unsung Aussie innovation story, says its turnaround specialist CEO The company is on a three-year mission to sing it [more…]
RareX streamlines board as it leans up for niobium and rare earths hunt
RareX board restructure to streamline operations and reduce costs as exploration at exciting niobium prospect begins CEO James Durrant promoted to MD as RareX assesses [more…]
Does anyone still remember how to play the ASX IPO game?
Notwithstanding the continuing macroeconomic and geopolitical risks, the current listings pipeline points to an increase in ASX IPO activity in 2024. A mineral exploration company [more…]
IPO Watch: The exploration IPO market begins to tick. Ever. So. Slightly.
They’ve been few and far between, but a handful of explorers are seeking IPOs to list on the ASX in 2024 A Brazilian rare earths [more…]
MoneyTalks: Sequoia initiates coverage on marine tech stock Veem, sees smooth waters ahead
Sequoia initiates coverage on Veem with a price target of $2.09 Veem specialises in marine propulsion systems, serving global markets Veem’s technology and strong market [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 16 July, 2024. Also known as World Snake Day. With more than 3,450 species of much-maligned, misunderstood serpent [more…]
Monsters of Rock: Bellevue high (and low) on gold and Sierra Rutile approached by new suitor
Bellevue ramps up production and nets $41m of free cash flow on gold highs A Sierra Leone petrol station owner has lobbed its own takeover [more…]
Closing Bell: Markets are in revolution and the ASX just stormed its psychological Bastille
ASX 200 punches through 8,000 on Monday All sectors higher Small cap miners led by Aldoro Resources Local markets surged into record territory on Monday, [more…]
PharmAust’s monepantel drug hits strategic milestone with selection for prestigious ALS treatment trial
Special Report: PharmAust has achieved a major milestone after its lead investigational drug, monepantel, was selected for inclusion in the prestigious HEALEY ALS Platform Trial [more…]
Long Shortz with Airtasker: Advertising skills on show in another multi-million media deal
Stockhead’s Sarah Hughan sits down with Airtasker (ASX:ART) CEO and founder Tim Fung to get the short end of the long story on the company’s [more…]
